VU0364572 (trifluoroacetate salt) 247egeline Fenebrutinib (GDC-0853) inhibits CD69 expression

Fenebrutinib (GDC-0853) inhibits CD69 expression on CD19+ B cells in human whole blood with an IC50 of 8

CHMFL-ABL-053 inhibited the proliferation of CML cell lines K562 (GI50 = 14 nM)

C[C@@H]1CC[C@]2(O[C@@H]1CC1=NC3=C(C(=CC=C3O1)NC)C([O-])=O)O[C@H]([C@H](C)C(=O)C1=CC=CN1)[C@H](C)C[C@H]2C

Receptor interacting protein-2 (RIP2) kinase

InChi: InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26

VU0364572 (trifluoroacetate salt) 247egeline Fenebrutinib (GDC-0853) inhibits CD69 expressionIC50: 477 172 nM VU0364572 is a M1 agonist. Alzheimer's disease (AD) is the leading cause of dementia worldwide, and no disease modifying therapy is availables. Selective M1 muscarinic acetylcholine receptor activation is an attractive mechanism for AD therapy since M1 mediates key effects on cognition, memory, and behavior and has potential for disease modifying effects on A formation and tau phosphorylation. In vitro: Previous study found that